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In this article, bone cells and their intercellular communications have been reviewed. Gap junctions and
hemichannels are the main routes of interactions in bone tissue. They play a substantial role in survival and cell
death, since pro-apoptotic signals can propagate through them. Different adhesion molecules are required for
apoptosis, particularly caspase family as well as noncaspase proteases. The disruption outcome of apoptosis could
result in bone-related diseases such as osteonecrosis. Anti-apoptotic strategies include inhibition of caspase, poly
[ADP-ribose] polymerase (PARP), and Bcl-2 proteins as well as induction of the PKB/Akt pathway and inhibitors of
apoptosis (IAP) family of proteins. Thus, understanding the mechanism of apoptosis gives detailed insights of
anti-apoptotic molecular targets. Based on these targets, different treatments were designed and produced such as
estrogen replacement therapy, administration of different bisphosphonates, raloxifene, calcitonin, sodium fluoride,
calcium, and vitamin D. As a result, new applicable drugs for treatment of related bone problems can be proposed
for clinical approach especially in the early stage of diseases.
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Bone as a mineralized and dynamic tissue supports and
protects the rest of body [1,2]. Different kinds of stimuli
affect the modeling and remodeling process in the bone
tissue [3,4]. These include endocrine, paracrine, and
autocrine factors, direct cell to cell communication
through gap junctions [5], with greater frequency of con-
nexin 43 (C×43), connexin 45 (C×45), and connexin 46
(C×46) [3] and cell-to-matrix communication through
hemichannels [6]. Besides, coordinated interaction bet-
ween bone cells plays a considerable role in bone
remodeling [7]. The main bone cells are osteoblasts,
osteocytes, and osteoclasts. Osteoblasts, which are re-
sponsible for maintaining skeletal architecture, originate
from pluripotent mesenchymal cells [2,8]. The most
abundant bone cells are osteocytes, differentiated osteo-
blasts, lying in the lacunar space enclosed by the bone
matrix [9,10]. Osteocytes compose lacunar-canalicular
network by their cytoplasmic dendrites that connect* Correspondence: Kerachianma@mums.ac.ir
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unless otherwise stated.them to each other and to cells on the bone surface, im-
portant for intracellular and extracellular communica-
tion (Figure 1) [11,12]. The third main class of bone
cells is osteoclast. Osteoclasts are giant multinucleated
cells with abundant mitochondria, multitudinous lyso-
somes, and free ribosomes [2,13]. These cells differenti-
ated from hematopoietic stem cells and are responsible
for bone resorption [14,15], that is dissolving and brea-
king down mineral and organic substrates [16].
This article provides an overview of what is currently
known about cell death in the osteoclast and osteoblast
lineages and how the death of these cells may be related
to clinically important bone diseases.Apoptosis and cell signaling
Cell death occurs under physiological and pathological
conditions and mediates through three pathways as
follows: apoptosis, autophagic cell death, and necrosis.
In contrast to necrosis (murdered cells), in apoptosis
(commit suicide) and autophagy process, cytoplasmic
membranes are maintained and cell body is completely
removed without any inflammation. However, if phago-
cytosis of the cell does not occur at the final stage of
apoptosis or autophagic process, the cells are removedntral. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Gap junction channels (GJC) and hemichannel (HC) in skeleton. As it is presented in this schematic presentation, HC composing
connexon placing on the body of osteocytes and osteoblasts respond to different signals which then control the transmission of different factors
among are PGE2, ATP, and PNS. Also, GJC forming by contacting two HC from adjacent cells present among osteoblasts, between dendritic
process of osteocytes, osteocyte-osteoblast as well as osteocyte-osteoclast. Various mechanical, hormonal, and biochemical factors affect the
expression and function of GJC. Altogether, cross-talks among bone cells through these junctions regulate bone biology.
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described by Kerr and colleagues in 1972 [17] as a
physiological situation characterized by distinguishable
morphological features such as nuclear changes (nuclear
chromatin condensation and nuclear fragmentation), cell
contraction, and losing attachment with adjacent cells.
Also, this process can be governed by regulatory factors
within the cell, and it can be induced or inhibited by
external factors [1,18]. Additionally, apoptosis is a regula-
tory program which has a noteworthy role during deve-
lopment and growth and maintaining the skeleton [19,20].
Although insufficient apoptosis occurs in cancer or auto-
immunity status, in degenerative diseases, immunodefi-
ciency, and infertility, cell death is accelerated [21].
Apoptotic process triggers by different pathways: one is
through mitochondrial (intrinsic pathway) and the other
is established by ligand activation via death receptors
(extrinsic pathway) (Figure 2) [20,22,23]. These receptors,
belonging to tumor necrosis factor (TNF) receptor super-
family, include CD95 (Fas), TNF-related apoptosis-
inducing ligand (TRAIL) R-1 and R-2, and TNF-R1 [21].
It has been postulated that, TRAIL as well as Fas pathways
mediate osteoclast apoptosis in human [23]. The bone is
to a certain extent inactive at the cellular level; thus, cell
death in this tissue is a critical issue in its physiology or
pathology [1]. During aging, the number of apoptotic oste-
oblasts and osteocytes increases, which ends up to falling
in osteoblast number and bone formation [24].The main adhesion molecules required for bone cell
development and apoptosis are integrins, especially αvβ3
(vibronectin receptor integrin) and α2β1 (collagen-binding
integrin), selectins, caspase, and a family of transmem-
brane proteins containing a disintegrin and metallopro-
tease domain (ADAMS) [13].
Caspase activity plays a key role in osteoblast apoptosis;
however, it may be also important in osteogenesis [25].
Caspase-activated DNAse (CAD), which breaks DNA
down to fragments, is activated in the early phase of apop-
tosis. Procaspase-8 and 9 are activated by death receptor
or through release of some molecules such as cytochrome
C from the mitochondria. Effector caspases (caspase-3, −6,
and −7) are activated after cleavage of procaspase-8 and 9.
As a final point, effector caspases cleave their targets
in the nucleus and cytoplasm. The release of protein-
activated caspase through the mitochondria is governed by
Bcl-2 family [22]. Bad, Bax, and Bid are the apoptotic
members of this family while Bcl-2 and Bcl-xL are consi-
dered as anti-apoptotic components [20]. Besides, other
pro-apoptotic proteins such as apoptosis-inducing factor
(AIF), Smac/DIABLO, and Omi/HtrA2 are released after
initial apoptotic stimuli [21]. Osteoblast apoptosis is
known as a complex process which is affected by various
factors including Bcl-2 family proteins, extracellular
signal-regulated kinase (ERK), mitogen-activated protein
kinases (MAPK), APJ/PI3-K/Akt, Janus kinase 2 (JAK2),
Fas [26,27], bone morphogenetic protein (BMP), and bone
Figure 2 Two apoptotic pathways are demonstrated. Extrinsic pathway which is triggered through death receptors and intrinsic one which is
caused by mitochondrial alterations. In the extrinsic pathway, binding death ligands to their receptors mainly CD95 (Fas), TNFR1, and TRAIL
triggers death signal through Fas-associated death domain (FADD) which then activates caspase-8. In the intrinsic pathway, cytochrome C (Cyt-C)
is released from the mitochondria and form apoptosome complex after attaching to apoptotic protease activating factor-1 (Apaf-1) followed by
activating caspase-9. The activated caspase-8 and 9 (initiator) activate the effector caspases 3, 6, and 7 which then results in cell death
characterized by obvious morphological and biochemical alterations. Furthermore, cell death depends on amounts of various members of Bcl2
family. For more information, read the text.
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gered via physiological or pathological factors [26], i.e., os-
teoblasts apoptosis can be induced by oxidized lipids
which then inhibit osteoblast differentiation through react-
ive oxygen species (ROS)-independent mechanisms. It has
been shown that functional forkhead box O3 (FoxO3) in
osteoblast not only reduces oxidative stress and osteoblast
apoptosis but also increases osteoblasts number, bone for-
mation rate, and mass [24]. Furthermore, matrix proteins,
such as fibronectin and osteopontin are involved in osteo-
blast apoptosis and survival [28]. The balance between the
birth of osteoblast from mesenchymal processors and the
apoptotic death would determine the number of cells [18].
Another important factor in apoptosis is p53 (tumor
suppressor protein) which is activated through ROS,
DNA damage, and other harmful stimuli such as onco-
gene activation and hypoxia. Extended p53 activation
leads to increased apoptosis through raised ROS levels.
Also, p53 modulates ROS production through various
mechanisms such as enhanced p66Shc protein which af-
fects generation of ROS in mitochondria along with con-
verting the oxidative signals into apoptosis. During
aging, phosphorylated forms of p53 and p66Shc are in-
creased in the bone as well as enhanced levels of ROS
and apoptotic osteoblasts [24].Although the life span of human osteoclasts is around
2 weeks, this time for osteoblasts is 3 months. Investiga-
tors have shown that growth factors and cytokines that
affect osteoclast and osteoblast development can also
stimulate their apoptosis [13].
Likewise, apoptosis in osteocytes increases with age
and is related with decreased levels of receptor activator
of nuclear factor kappa-B (NF-kβ) ligand (RANKL) and
sclerostin protein in the bone. Accordingly, oxidative
stress or other mechanisms related to aging can affect
bone remodeling [24].
Since osteocytes are embedded in mineralized matrix,
scavengers cannot reach them and osteocyte death
causes cell disruption. Release of immunostimulatory
molecules from lacunae activates macrophages produ-
cing proinflammatory cytokines such as TNF-α, interleu-
kin (IL)-6, and IL-1. Current cytokines trigger bone loss.
Besides, RANKL expression is induced via IL-6 as well
as IL-1. It has been shown that apoptotic osteocytes
are characterized by degraded DNA in lacunae and
increased expression of specific factors, promoting
osteoclastogenesis. Besides, bone resorption caused by
osteocytes death is via release of intracellular content of
dead osteocytes through canicular system [12]. Probably,
matrix metalloproteinase (MMP)-resistant mutant of
Mollazadeh et al. Journal of Orthopaedic Surgery and Research  (2015) 10:15 Page 4 of 7type I collagen induces osteocyte apoptosis. The osteo-
cyte network suppresses bone formation under physio-
logical conditions. Interestingly, osteocyte apoptosis is
induced by strain causing microdamage in the bone [18].
Overall, microcracks and fatigue as well as pro-apoptotic
factors trigger osteocyte death, which could activate osteo-
clasts. In contrast, there are some factors not only causing
osteocyte survival but also osteoblast activation [10].
Altogether, apoptosis as a part of a normal physiological
process could be dysregulated and causes apoptotic-
related bone diseases.
Apoptosic-related bone diseases
Extensive cell communication network made by osteo-
cytes could detect mechanical loadings and microdam-
age to the bone tissue. Drugs and bone active hormones
control the bone strength and integrity of this network
through the regulation of osteocyte cell death [29].
Irregularities in apoptosis account for different diseases
which result from either extensive or inadequate cell
death [20]. Accordingly, interruption in bone remo-
deling, characterized by survival and apoptosis of bone
tissue leads to diseases such as osteoporosis or malig-
nant osteolysis [23].
In osteoarthrosis, hyperparathyroidism, and Paget’s
disease of bone (PDB), apoptosis in osteoclasts is evident
[1]. However, it has been revealed that in the osteopo-
rotic bone, the rate of apoptosis is lower than that in the
osteoarthritic bone [19]. Other bone problems mediated
by osteoclast apoptosis are post-menopausal osteopo-
rosis and rheumatoid arthritis (RA). It was revealed that
Bcl-xL, an anti-apoptotic protein of the Bcl-2 family, is
overexpressed in the inflamed joints of TNF transgenic
mice and RA patients [30].
Osteoblast apoptosis brings about different bone prob-
lems especially osteoporosis [26]. Apoptosis in osteoblast
lineage has been reported in the proximal femur par-
ticularly in the femoral head from elderly than young
subjects [1]. Weinstein and his colleagues showed that
glucocorticoid-induced osteonecrosis of the femoral
head is not necrosis; instead, prominent apoptosis of
cancellous lining cells and osteocytes occurs. Osteocyte
apoptosis induced by glucocorticoid could disrupt the
mechanosensory function of the osteocyte network and
thus triggers a sequence of events leading to disintegra-
tion of the femoral head [31]. However, many factors are
involved in etiopathogenesis of osteonecrosis such as al-
cohol or glucocorticoids [32,33]. We studied the role of
glucocorticoids in the development of osteonecrosis
[34]. Glucocorticoids induce osteonecrosis through vari-
ous mechanisms, most importantly through its direct ef-
fect on bone and vascular cells causing osteoblast-
osteocyte apoptosis and vascular bedding damage [35].
The effects of glucocorticoid on osteocytes lead toreduction in fluid transportation in lacunar-canalicular
system, vascularity, and strength of the bone [36]. So,
glucocorticoids are considered as great inhibitors of
bone formation since they stimulate osteoblast apoptosis
[24,35]. The mechanism by which glucocorticoids stimu-
late apoptosis is reported to depend on interactions be-
tween glucocorticoid receptors, dimerization of
receptors and regulation of gene expression. Dexameta-
sone (Dex), as a glucocorticoid, may increase the expres-
sion of pro-apoptotic genes inducing apoptosis [37].
Furthermore, aminobisphosphonates used for the treat-
ment of osteoporosis and other disorders of bone re-
sorption may induce apoptosis in osteoblasts and inhibit
their differentiation [38]. Increased expression of indu-
cible nitric oxide synthase (iNOS) in osteonecrotic pa-
tients elevates toxic levels of NO, which have deleterious
effects on osteoblastogenesis followed by high amounts
of apoptotic cells [32].
It was reported that increased apoptosis in myeloma
bone microenvironment accounts for impaired new
bone formation due to high amounts of cytokine as well
as physical interaction among osteoblasts and malignant
plasma cells [39]. Studies also have shown that patho-
genesis of osteosarcoma is related to abnormal function
of p53 and the retinoblastoma gene [1]. Altogether,
osteoblast apoptosis which is to some extent influenced
by lack of sex steroid, excess of glucocorticoids, or aging
results in bone loss [19].
Anti-apoptotic factors in bone loss
Anti-apoptotic procedures in the case of pathologically in-
creased cell death are as follows: inhibition of caspase,
poly [ADP-ribose] polymerase (PARP), and Bcl-2 proteins
as well as induction of the PKB/Akt pathway and the in-
hibitor of apoptosis (IAP) family of proteins [20]. It was
shown that overexpression of Bcl-2 prevents apoptosis
through cytochrome C release inhibition [40]. Activation
of PKB/Akt by kinases like phosphoinoside-dependent
kinase 1 (PDK1) creates protection against apoptosis [41].
Also, the anti-apoptotic effect of IAP occurs by sup-
pressing enzymatic function of caspases [42]. Various
apoptotic-related diseases can be treated by inhibition of
caspase activities followed by a decrease in apoptosis and
organ function refining. It was reported that Casp3Inh
(Z-DEVD-FMK) inhibits caspase-3 activity which could
affect bone mineral density (BMD) by upregulation of
transforming growth factor (TGF-β)/Smad2 signaling
pathway in bone marrow stromal stem cells (BMSSCs).
Furthermore, it was proved that Z-DEVD-FMK prevents
osteogenic differentiation in human BMSSCs through in-
hibition of caspase-3 activity. Therefore, caspase-3 plays a
considerable role in bone development and metabolism
[25]. Besides, survival signals can be generated by intracel-
lular kinase cascade including states, ERK, Akt, and
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focal adhesion kinase (FAK) activation activates PI3K and/
or the MAP kinase cascade, which prevents apoptosis
[43]. PI3K, which is activated through different extracellu-
lar signals such as insulin and insulin-like growth factor I
(IGF-I), significantly is involved in several anti-apoptotic
pathways as well as enhancing proliferation by Akt/PKB.
Phosphatase and tensin homologue (PTEN) as a tumor-
suppressor gene prevents the activity of PI3K. Lack of
PTEN increases bone mass through promoting the num-
ber of osteoblasts probably via the deceleration of apop-
tosis [26]. Recent studies suggest that Wnt/b-catenin
activates anti-apoptotic signaling pathways that primarily
act through Src/ERK and PIK3/Akt [18]. Activation of
NF-kB is considered as an inhibitor of apoptosis induced
by death receptor [30]. TGF-β, IGF-I, fibroblast growth
factor 2 (FGF-2), and IL-6 have anti-apoptotic effects on
cultured osteoblastic cells. Moreover, MMP-resistant mu-
tant of type I collagen has the same effect on these cells
[18]. IL-1 is considered as an anti-apoptotic factor which
its lack results in increase osteoclast apoptosis by di-
minishing prostaglandins concentration or other anti-
apoptotic factors. Osteoclasts apoptosis can be prevented
by 1,25 (OH)2 vitamin D3 and parathyroid hormone
(PTH) probably through RANKL stimulation or reduction
in osteoprotegerin (OPG) expression. It was suggested that
PI3K/Akt signaling pathway has a positive regulatory effect
on osteoclast formation. Macrophage colony-stimulating
factor (M-CSF) and RANKL stimulate the expression of
anti-apoptotic gene Bcl-2 and Bcl-xL and x-linked inhibi-
tor of apoptosis protein (XIAP). Besides, RANKL-activated
NF-kB is required for osteoclast survival [43]. NF-kB,
which has an anti-apoptotic effect on some cell types
including osteoclasts, is activated by binding TNF to its
receptor [24]. In contrast, strontium ranelate enhances
osteoclast apoptosis through a calcium-sensing receptor
(CaR)-dependent mechanism [44]. OPG, a TRAIL recep-
tor, plays a key role in the inhibition of apoptosis induced
by TRAIL [30]. Similar to M-CSF, IL-1, TNF-α, and IL-6,
there are other cytokines which inhibit osteoclast apop-
tosis. Inducer factors of bone resorption inhibit osteoclast
apoptosis, while their suppression stimulates the apoptosis.
Estrogen, 17f-oestradiol (E2), increases the number of
apoptotic osteoclasts; however, the effect of E2 on osteo-
clast could be reversed by a pan-specific anti-TGF anti-
body as well as estrogen agonist/antagonist tamoxifen.
Likewise, integrins such as αvβ3 integrin has a similar
effect on the bone which increases osteoclast apoptosis.
Other findings suggest that interactions between osteoclast
matrix regulate osteoclast apoptosis [1]. The same cyto-
kines and growth factors affect not only osteoblast and
osteoclast development but also their apoptosis. In this
case, IL-6 blocks apoptosis of osteoblastic cells of animal
and human as well as osteoclasts and their processors.Also, it has been reported that TGF-β has an anti-
apoptotic effect on osteoblast while it could increase
osteoclast apoptosis [13]. Several endogenous stimuli
(systemic, local, or mechanical) have anti-apoptotic effects
on bone cells through C×43 or cell-to-cell communication.
Similarly, anabolic and anti-catabolic inducers have
anti-apoptotic effects on bone-forming cells such as the
anabolic effects of PTH, activators of the Wnt signaling
pathway, and mechanical stimuli [45].
Anti-apoptotic drugs and treatment of bone loss
Bisphosphonates are anti-catabolic drugs administering
in disorders including malignant osteolysis, osteoporosis,
and PDB [30]. It was reported that bisphosphonate drug
(alendronate) needs C×43 hemichannels to inhibit apop-
tosis in osteoblast through activation of src-ERK [38,45,46].
It is supposed that alendronate enters to the cell after
inducing C×43 opening. Alendronate causes closure of
C×43 hemichannels by phosphorylation of the C-terminal
cytoplasmic domain after interaction with Src kinase, the
upstream activator of ERK [47]. Besides, the current drug
has the same effect on osteocytes via cytoplasmic ERK
activation and influencing the canonical nuclear transloca-
tion pathway signaling cascade [3,48]. Likewise, alendro-
nate has a prevailing effect on inhibition of osteoclastic
resorption in glucocorticoid-induced bone loss [45]. Since
bisphosphonate increases osteoclast apoptosis in human
and rodents, it is considered as a potential treatment in
PDB and post-menopausal osteoporosis [1]. As the mech-
anism of action of bisphosphonates in osteoblasts and os-
teocytes depends on C×43 hemichannels, the current
compounds are considered as an anti-apoptotic pharma-
cological target [38,45,46]. Because sex steroid paucity as
well as glucocorticoids induce bone apoptosis, protection
against them preserves bone cell viability [45]. Hormones,
estrogens, and androgens inhibit apoptosis in osteoblasts
and osteocytes. Also, 1,25-dihydroxyvitamin D3 has anti-
apoptotic effects on osteoblasts. Additionally, PTH and
PTH-related protein (PTHrP) have the similar effects on
cultured osteoblasts of rat, murine, and human via inacti-
vation of Bad, enhanced transcription of survival genes
such as Bcl-2, and cAMP-activated protein kinase A [18].
Not surprisingly, some natural compounds have thera-
peutic effects such as reveromycin A (RM-A). This com-
pound, a small natural product with three carboxylic
groups isolated from the genus Streptomyces, induces
apoptosis in osteoclasts through induction of cytochrome
C release and caspase 3 activation [49]. It was shown that
puerarin, which is extracted from the root of a wild legu-
minous creeper with estrogen-like structure, has an anti-
apoptotic effect on human osteoblasts by activation of
ERK signaling pathway. So, it could be used as a potential
drug for osteoporosis treatment [26]. Similarly, vaspin, an
adipocytokine isolated from visceral white adipose tissue,
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ing the MAPK/ERK signaling pathway [50]. Besides, adre-
nomedullin (ADM), synthesized and secreted by a variety
of cells, enhances the number of osteoblasts and increases
bone growth. Recently, it was shown that ADM possess
an osteoblastic anti-apoptotic effect through calcitonin
gene-related peptide1 (CGRP1) receptor-MEK-ERK path-
way [51]. Apelin, a peptide expressed by adipocyte and
osteoblast, inhibits apoptosis mediated by serum
deprivation in human osteoblasts through APJ/PI-3 kin-
ase/Akt signaling pathway. It should be noted that APJ is
an orphan G protein-coupled receptor and apelin is its en-
dogenous ligand. Apelin has a protective role in
glucocorticoid-induced apoptosis [52]. As mentioned earl-
ier, glucocorticoids suppress the number of osteoblasts
through reducing ERK activation by mitogens. It has been
shown that vanadate (a protein tyrosine phosphatase in-
hibitor) could act as a survival factor since it inhibits
apoptosis mediated by glucocorticoids in pre-osteoblasts
and osteocytes [37]. There are lines of evidence that tau-
rine, the most plentiful intracellular amino acid in
humans, could conserve osteoblast through taurine trans-
porter (TAUT)/ERK pathway. Moreover, the mechanism
of the taurine is associated with reduction of
mitochondria-dependent pathways that is decreasing the
release of cytochrome C [53]. Taken together, estrogen re-
placement therapy (ERT), different bisphosphonates (e.g.,
alendronate), the selective estrogen receptor modulator
(SERM), raloxifene, calcitonin, sodium fluoride, calcium,
and vitamin D could be used as modulators to treat bone
diseases. Androgen and estrogen inhibit apoptosis in oste-
oblasts and osteocytes; thus, estrogenic, androgenic, or
even nonsteroidal compounds are considered as potential
drugs for osteoporosis treatment [13].
Conclusion
To sum up, bone diseases especially the intolerable ones
could be treated in the early stages of the disease via
therapeutic factors triggering the anti-apoptotic path-
ways. Based on preclinical studies, molecular routes en-
courage us to think about practical target achievements.
However, molecular therapies should be used with more
care because of their bilateral role in some cases.
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